Nanodrug modified with engineered cell membrane targets CDKs to activate aPD-L1 immunotherapy against liver metastasis of immune-desert colon cancer.

MLA

Ding, Dongbing, et al. “Nanodrug Modified with Engineered Cell Membrane Targets CDKs to Activate APD-L1 Immunotherapy against Liver Metastasis of Immune-Desert Colon Cancer.” Journal of Controlled Release, vol. 369, May 2024, pp. 309–24. EBSCOhost, https://doi.org/10.1016/j.jconrel.2024.03.052.

APA

Ding, D., Liang, R., Li, T., Lan, T., Li, Y., Huang, S., He, G., Ren, J., Li, W., Zheng, Z., Chen, T., Fang, J., Huang, L., Shuai, X., & Wei, B. (2024). Nanodrug modified with engineered cell membrane targets CDKs to activate aPD-L1 immunotherapy against liver metastasis of immune-desert colon cancer. Journal of Controlled Release, 369, 309–324. https://doi.org/10.1016/j.jconrel.2024.03.052

Chicago

Ding, Dongbing, Rongpu Liang, Tan Li, Tianyun Lan, Yiquan Li, Shengxin Huang, Guanhui He, et al. 2024. “Nanodrug Modified with Engineered Cell Membrane Targets CDKs to Activate APD-L1 Immunotherapy against Liver Metastasis of Immune-Desert Colon Cancer.” Journal of Controlled Release 369 (May): 309–24. doi:10.1016/j.jconrel.2024.03.052.